Sure Bud , what I'd like to add is we have 4 clinical trials running and an expanded staff with a couple recent hires and I'm sure Schweity and Loar are fairly, but not excessively compensated. We actually are running very lean compared to how we are progressing. This is a STRONG BASH because it's nonsense and you know it.
We know they aren't doing a financing any time soon especially under a buck when we face Nasdaq compliance issues and we know the plan is "full speed ahead" for Phase III so that only leaves a partnership or buyout. Wonder why we no longer need an IR person? How about no CC attached to the Q3 results? say no more - see you at $10.00++
KBIO - winding down operations, laying off all staff, stopping development of Phase I and II Oncology assets, market cap $68 million with about $8 million cash
OXG - raming up trials, expanding and hiring staff, accelerating development of Phase II and III Oncology assets, market cap $20 million with $30 million cash and no debt!!!
What a joke c'mon Schweity - do sumptin'